Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Caffeine and New Zealand Blackcurrant on Endurance Performance in Women

ClinicalTrials.gov ID: NCT07951697

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07951697. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 12:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Independent and Combined Effects of Caffeine and New Zealand Blackcurrant Extract on Endurance Exercise Performance, Substrate Oxidation, and Cognitive Function in Endurance-Trained Women: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Caffeine (CAF) and New Zealand blackcurrant extract (NZBC) are nutritional supplements that have been investigated for their potential effects on endurance exercise performance, energy metabolism, and cognitive function. Caffeine is a stimulant that may improve endurance performance, alertness, and perceived exertion during exercise, while NZBC contains anthocyanins that may influence fat oxidation and physiological responses during endurance exercise. Although previous research has examined these supplements individually, limited research has investigated their combined effects. This study examined their independent and combined effects on endurance exercise performance, substrate oxidation, and cognitive function in healthy, endurance-trained women aged 18-40 years. Endurance exercise performance was the primary outcome, while substrate oxidation and cognitive function were secondary outcomes. The study used a randomized, double-blind, placebo-controlled crossover design involving four experimental conditions: placebo (PL; 600 mg maltodextrin), NZBC (600 mg containing 210 mg anthocyanins), CAF (6 mg/kg body weight), and NZBC+CAF at the same respective doses. Participants completed the conditions in a randomized order, with seven-day supplementation periods separated by seven-day washout intervals to minimize potential carryover effects. Neither participants nor researchers conducting the assessments knew which treatment was administered. During each experimental testing session, participants first underwent body weight, resting heart rate, and blood pressure measurements before ingesting their final assigned supplement dose under researcher supervision. After a two-hour waiting period, participants completed a cognitive function assessment and questionnaires evaluating readiness to perform using a visual analog scale (VAS), caffeine consumption, and sleep quality. Blood lactate, glucose, and ratings of perceived exertion (RPE) were measured before a treadmill running test assessing endurance exercise performance and time to exhaustion. During exercise, RPE was recorded every three minutes, while respiratory gas exchange measurements were used to determine carbohydrate oxidation, fat oxidation, maximal fat oxidation, and energy expenditure. Blood lactate and glucose concentrations were measured immediately and five minutes after exercise, and heart rate and blood pressure were assessed one minute after exercise.

Study identification

NCT ID
NCT07951697
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Enrollment
20 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 40 Years
Sex
Female
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 12, 2025 (Actual)
Primary completion
Apr 29, 2025 (Actual)
Completion
Apr 29, 2025 (Actual)
Last update posted
Nov 20, 2026

2025

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Exercise Physiology and Nutrition Laboratory (EPNL) at Jacksonville State University, Jacksonville Alabama 36265-1724 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07951697, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2026 · Synced Nov 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.